Series A · Healthtech · Malmo, Sweden · Founded 2016 · 11–50 employees
Flow Neuroscience has developed Europe's first and only medically approved transcranial direct current stimulation (tDCS) headset combined with a therapy app for treating depression at home. Founded in 2016 by clinical psychologist Daniel Månsson and neuroscientist Erik Rehn, the company offers a medication-free alternative to traditional depression treatment with no side effects. Their clinical trial data shows 57% of users become depression-free and over two-thirds see symptom improvement. The company has raised over $20 million from leading investors like Khosla Ventures and is already being used by the NHS, over 200 private clinics, and 25,000 users across Europe, with plans for FDA approval and US expansion.
No open roles listed right now.